REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson
CARY, N.C., July 30, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced that it has been selected by Kadmon (Nasdaq: KDMN) as a specialty pharmacy provider for REZUROCK™ (belumosudil) for the treatment of adult and pediatric... (Source: McKesson News)
Source: McKesson News - July 30, 2021 Category: Information Technology Source Type: news

McKesson Raises Quarterly Dividend by 12% to $0.47 Per Share
IRVING, Texas, July 26, 2021 — The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of $0.47 per share of common stock, a 12% increase from $0.42 per share in the prior quarter. The dividend will be payable on October 1, 2021, to stockholders of reco... (Source: McKesson News)
Source: McKesson News - July 26, 2021 Category: Information Technology Source Type: news

McKesson Corporation Announces Pricing and Upsizing of Tender Offer
IRVING, Texas, July 22, 2021 — McKesson Corporation (NYSE: MCK) (the “Company”) today announced the determination of the Full Tender Offer Consideration, as shown in the table below, for its previously announced cash tender offer to purchase up to $500,000,000 aggregate principal amount (the “Offer”... (Source: McKesson News)
Source: McKesson News - July 22, 2021 Category: Information Technology Source Type: news

McKesson Corporation Announces Early Tender Results and Intention to Increase the Tender Cap
IRVING, Texas, July 22, 2021 -- McKesson Corporation (NYSE: MCK) (the “Company”) today announced the early tender results as of the Early Tender Time (as defined below) in connection with its previously announced cash tender offer to purchase up to $500,000,000 (subject to increase, the “Tender Cap”... (Source: McKesson News)
Source: McKesson News - July 22, 2021 Category: Information Technology Source Type: news

Distributors Announce Proposed Opioid Settlement Agreement
CONSHOHOCKEN, PA, DUBLIN, OH and IRVING, TX, July 21, 2021 —AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have negotiated a comprehensive proposed settlement agreement which, if all conditions are satisfied, would result in the settlemen... (Source: McKesson News)
Source: McKesson News - July 21, 2021 Category: Information Technology Source Type: news

Distributors Reach Opioid Settlement with New York State
CENTRAL ISLIP, New York, July 20, 2021 —AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have agreed to pay up to $1.179 billion in a settlement with the State of New York and its participating subdivisions, including Nassau and Suffolk Cou... (Source: McKesson News)
Source: McKesson News - July 20, 2021 Category: Information Technology Source Type: news

McKesson Named One of the Best Places to Work for Disability Inclusion
IRVING, Texas, July 13, 2021 — For the sixth consecutive year, McKesson is honored as one of the “Best Places to Work for Disability Inclusion” by Disability Equality Index (DEI). McKesson also earned a top score of 100% for displaying best-in-class commitments to culture and leadership, accessibilit... (Source: McKesson News)
Source: McKesson News - July 13, 2021 Category: Information Technology Source Type: news

McKesson Corporation Announces Offer to Purchase $500 Million Aggregate Principal Amount of Debt
IRVING, Texas, July 8, 2021 -- McKesson Corporation (NYSE: MCK) (the “Company”) today announced the commencement of a cash tender offer to purchase up to $500,000,000 (subject to increase, the “Tender Cap”) aggregate principal amount (the “Offer”) of its outstanding 6.00% Notes due 2041 (the “6.00% ... (Source: McKesson News)
Source: McKesson News - July 8, 2021 Category: Information Technology Source Type: news

McKesson Corporation Enters Agreement to Sell Certain European Businesses to the PHOENIX Group
Transaction enhances McKesson ’s focus and commitment to future investments in strategic growth, including oncology and biopharma services, and core pharmaceutical and medical distributionAgreement includes the sale of McKesson Europe businesses in France, Italy, Ireland, Portugal, Belgium, and Slove... (Source: McKesson News)
Source: McKesson News - July 7, 2021 Category: Information Technology Source Type: news

McKesson Corporation to Announce First Quarter Fiscal 2022 Results on August 4, 2021
IRVING, Texas, June 30, 2021 —McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2022 financial results after market close on Wednesday, August 4, 2021. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financi... (Source: McKesson News)
Source: McKesson News - June 30, 2021 Category: Information Technology Source Type: news

TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson
CARY, N.C., June 21, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group, as a specialty pharmacy provider for TRUSELTIQTM (infigrati... (Source: McKesson News)
Source: McKesson News - June 21, 2021 Category: Information Technology Source Type: news

LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty pharmacy provider for LUMAKRASTM (sotorasib) for the treatment of patients with KRAS G12C-mutated locally advanced ... (Source: McKesson News)
Source: McKesson News - June 11, 2021 Category: Information Technology Source Type: news

First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research
Over 80 percent of non-small cell lung cancer detected at Stage 4Fewer than 50 percent of patients had five or more biomarker testsMedian time from diagnosis to first-line therapy is about five weeks (Source: McKesson News)
Source: McKesson News - June 4, 2021 Category: Information Technology Source Type: news

US Oncology Research, The US Oncology Network and Ontada Announce Clinical Data Showcased in Plenary and Oral Sessions at ASCO Annual Meeting
THE WOODLANDS, Texas, June 3, 2021 — US Oncology Research, The US Oncology Network (The Network), and OntadaTM announce they contributed to more than 75 studies covering topics including gynecologic cancer, lung cancer and immunotherapy which will be presented at the upcoming 2021 American Society o... (Source: McKesson News)
Source: McKesson News - June 3, 2021 Category: Information Technology Source Type: news

Community Pharmacies with Health Mart, Health Mart Atlas Administer 1 Million COVID-19 Vaccine Doses
IRVING, Texas, May 19, 2021 —As of today, 1,370 community pharmacies affiliated with Health Mart® and Health Mart Atlas™ have collectively administered one million COVID-19 vaccine doses1. For underserved and rural communities, vaccine access can be a significant challenge in the initiative to reach ... (Source: McKesson News)
Source: McKesson News - May 19, 2021 Category: Information Technology Source Type: news

McKesson Reports Fiscal 2021 Fourth-Quarter Results and Full-Year Results
Fourth-Quarter and Full-Year Highlights: (Source: McKesson News)
Source: McKesson News - May 6, 2021 Category: Information Technology Source Type: news

McKesson Commits to Set Science-Based Targets to Reduce Greenhouse Gas Emissions
IRVING, Texas, May 5, 2021 — McKesson Corporation, a global leader in healthcare, has signed a commitment letter to the Science Based Targets initiative (SBTi), joining over 1,300 companies to commit to setting ambitious targets to reduce greenhouse gas emissions. (Source: McKesson News)
Source: McKesson News - May 5, 2021 Category: Information Technology Source Type: news

McKesson Declares Quarterly Dividend
IRVING, Texas, April 29, 2021 --  The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 42 cents per share of common stock. The dividend will be payable on July 1, 2021, to stockholders of record on June 1, 2021. (Source: McKesson News)
Source: McKesson News - April 29, 2021 Category: Information Technology Source Type: news

McKesson Announces N. Anthony Coles, M.D. Will Not Stand for Re-Election to McKesson Board of Directors
IRVING, Texas, April 19, 2021 — McKesson Corporation today announced that N. Anthony Coles, M.D., informed the company he will not stand for re-election to the McKesson Board of Directors at its next annual shareholders meeting in July 2021. (Source: McKesson News)
Source: McKesson News - April 19, 2021 Category: Information Technology Source Type: news

NULIBRY (fosdenopterin), First and Only FDA-Approved Therapy to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency Type A, Available Exclusively at Biologics by McKesson
CARY, N.C., April 19, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Origin Biosciences, Inc., an affiliate of BridgeBio Pharma, Inc. (BridgeBio), as the exclusive specialty pharmacy provider for NULIBRYTM (fosdenopterin... (Source: McKesson News)
Source: McKesson News - April 19, 2021 Category: Information Technology Source Type: news

The US Oncology Network continues its rapid growth and enhances surgical expertise with addition of physicians from Texas Colon & amp; Rectal Specialists as a part of Texas Oncology
THE WOODLANDS, Texas, April 1, 2021 —The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of phys... (Source: McKesson News)
Source: McKesson News - April 1, 2021 Category: Information Technology Source Type: news

McKesson Corporation to Announce Fourth Quarter Fiscal 2021 Results on May 6, 2021
IRVING, Texas, April 1, 2021 -- McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2021 financial results after market close on Thursday, May 6, 2021. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financi... (Source: McKesson News)
Source: McKesson News - April 1, 2021 Category: Information Technology Source Type: news

McKesson Approved as QCDR for 2021 MIPS Program Year
IRVING, Texas, March 25, 2021 — For the fifth consecutive year, McKesson has received approval from The Centers for Medicare& Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). As a CMS-approved QCDR, Practice Insi... (Source: McKesson News)
Source: McKesson News - March 25, 2021 Category: Information Technology Source Type: news

Ontada Appoints Susan Shiff, Ph.D., MBA, as President
LAS COLINAS, TEXAS, Mar. 22, 2021 —OntadaTM, McKesson’s oncology technology and insights business, announced today that respected real-world data expert Susan Shiff has joined as President. In this role, Shiff will continue to build on Ontada’s momentum in delivering real-world insights to transform ... (Source: McKesson News)
Source: McKesson News - March 22, 2021 Category: Information Technology Source Type: news

McKesson launches ScriptPAS, empowering oncology practices to reduce time to therapy while enhancing patient care
IRVING, Texas, March 18, 2021 — McKesson, a global leader in healthcare dedicated to supporting the full continuum of care, announced the launch of ScriptPAS™, a pharmacy management solution for oncology practices powered by Biologics by McKesson specialty pharmacy. ScriptPAS is a fee-for-service of... (Source: McKesson News)
Source: McKesson News - March 18, 2021 Category: Information Technology Source Type: news

McKesson Expands Integrated Pharmacy Services for Specialty Clinics
IRVING, Texas, March 16, 2021 — McKesson Corporation, a global healthcare company, announces a new collaboration with Vanderbilt Health Rx Solutions (VHRxS), a national leader in specialty pharmacy strategy and implementation, to offer VHRxS’s full suite of specialty pharmacy consulting services to ... (Source: McKesson News)
Source: McKesson News - March 16, 2021 Category: Information Technology Source Type: news

FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 12, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal ... (Source: McKesson News)
Source: McKesson News - March 12, 2021 Category: Information Technology Source Type: news

McKesson Begins Distributing the Johnson & amp; Johnson COVID-19 Vaccine
IRVING, Texas, March 1, 2021 — As a centralized distribution partner for the U.S. government’s COVID vaccine distribution effort, McKesson today began distributing the COVID-19 vaccine received from Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson& Johnson. The ... (Source: McKesson News)
Source: McKesson News - March 1, 2021 Category: Information Technology Source Type: news

Ontada ’s Clear Value Plus Provides 800,000th Chemotherapy Treatment Decision
IRVING, TEXAS, Feb. 18, 2021 —OntadaTM, McKesson’s oncology technology and insights business, recently reached a major milestone by providing its 800,000th evidence-based treatment option through Clear Value PlusSM. As the #1 most-used oncology pathway by medical oncologists, Clear Value Plus is reli... (Source: McKesson News)
Source: McKesson News - February 18, 2021 Category: Information Technology Source Type: news

McKesson RxOwnership Expands Commitment to Pharmacy Owners
IRVING, Texas, Feb. 11 — McKesson RxOwnership®, a no-fee resource for independent pharmacies seeking financial and ownership transaction guidance, signed a new five-year commitment with the National Community Pharmacists Association (NCPA) to sponsor the Pharmacy Ownership Workshop series. This rene... (Source: McKesson News)
Source: McKesson News - February 11, 2021 Category: Information Technology Source Type: news

MYLUNG Study Launches, Aiming to Advance Use of Precision Medicine for Metastatic Non-Small Cell Lung Cancer Patients
Unique, collaborative real-world research consortium will study up to 12,000 NSCLC patients in the community setting over five yearsMYLUNG to deepen understanding of barriers and address challenges to improve care for lung cancer patients, including those with targetable mutations (Source: McKesson News)
Source: McKesson News - February 4, 2021 Category: Information Technology Source Type: news

McKesson Reports Fiscal 2021 Third-Quarter Results
Third-Quarter Highlights, Year-over-Year: (Source: McKesson News)
Source: McKesson News - February 2, 2021 Category: Information Technology Source Type: news

McKesson Declares Quarterly Dividend
IRVING, Texas, January 28, 2021 -- The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 42 cents per share of common stock. The dividend will be payable on April 1, 2021, to stockholders of record on March 2, 2021. (Source: McKesson News)
Source: McKesson News - January 28, 2021 Category: Information Technology Source Type: news

McKesson Recognized as one of the “Best Places to Work for LGBTQ Equality” for Eighth Year in a Row
IRVING, Texas, Jan. 28, 2021 — For the eighth consecutive year, McKesson Corporation is honored as one of the “Best Places to Work for LGBTQ Equality” by the Human Rights Campaign (HRC) Foundation. McKesson achieved 100 percent on the HRC’s 2021 Corporate Equality Index (CEI), a nationally recognized... (Source: McKesson News)
Source: McKesson News - January 28, 2021 Category: Information Technology Source Type: news

ORGOVYX (relugolix), the First FDA-Approved Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer, Available at Biologics by McKesson
CARY, N.C., Jan. 21, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Myovant Sciences as a specialty pharmacy provider for ORGOVYXTM (relugolix) for the treatment of advanced prostate cancer. (Source: McKesson News)
Source: McKesson News - January 21, 2021 Category: Information Technology Source Type: news

McKesson Statement on Political Contributions
IRVING, Texas, Jan. 15, 2021 — McKesson is committed to fostering positive change in the world. In accordance with our ICARE and ILEAD values, the McKesson Employees’ Political Action Committee (PAC) has suspended contributions to all Members of Congress, including those who, even after a violent and... (Source: McKesson News)
Source: McKesson News - January 15, 2021 Category: Information Technology Source Type: news

McKesson Corporation Announces Third Quarter Fiscal 2021 Earnings Release Date and Participation in January Conferences
IRVING, Texas, December 28, 2020 – McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2021 financial results before market open on Tuesday, February 2, 2021. The company will host a live webcast of the earnings conference call for investors at 8:00 AM Eastern Time to review its fi... (Source: McKesson News)
Source: McKesson News - December 28, 2020 Category: Information Technology Source Type: news

McKesson Fills Initial Government Orders for Moderna ’s COVID-19 Vaccine
IRVING, Texas, Dec. 20 — As part of Operation Warp Speed, the U.S. government’s public-private partnership to deliver COVID-19 vaccines to Americans, and under the direction of the Centers for Disease Control and Prevention (CDC), McKesson began distributing Moderna’s COVID-19 vaccines and the ancil... (Source: McKesson News)
Source: McKesson News - December 20, 2020 Category: Information Technology Source Type: news

McKesson and TailorMed Collaborate to Reduce Patient Financial Barriers to Care
IRVING, Texas and SAN FRANCISCO, Dec. 16, 2020 —McKesson, a global healthcare leader that has spearheaded technologies and services that address patient affordability, and TailorMed, a healthcare technology company founded to help patients and providers tackle the financial challenges of care deliver... (Source: McKesson News)
Source: McKesson News - December 16, 2020 Category: Information Technology Source Type: news

Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities
IRVING, TX, and THOUSAND OAKS, CA, Dec. 4, 2020 —McKesson and Amgen (NASDAQ:AMGN), one of the world’s leading biotechnology companies, have signed a strategic agreement to help improve cancer care in community oncology settings. Today, 1 in 5 cancer patients receives an Amgen medicine, while McKesson... (Source: McKesson News)
Source: McKesson News - December 4, 2020 Category: Information Technology Source Type: news

McKesson Launches Ontada, an Oncology Technology and Insights Business Dedicated to Help Advance Cancer Research and Care
IRVING, TX, Dec. 3, 2020 —McKesson Corporation today announced the launch of Ontada, an oncology technology and insights business designed to support innovation, acceleration, and evidence generation to drive better outcomes for patients with cancer. (Source: McKesson News)
Source: McKesson News - December 3, 2020 Category: Information Technology Source Type: news

US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and Exposition
THE WOODLANDS, Texas, Dec. 2, 2020 — During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, principal investigators from The US Oncology Network (The Network and US Oncology Research will share detailed results from 30 studies covering topics that include Hodgkin lymphom... (Source: McKesson News)
Source: McKesson News - December 2, 2020 Category: Information Technology Source Type: news

McKesson Appoints Dr. Kelvin A. Baggett to Chief Impact Officer
IRVING, Texas, November 19, 2020 – McKesson Corporation (NYSE:MCK) today announced that the company has appointed Dr. Kelvin A. Baggett to the newly created role of chief impact officer, effective November 30, 2020. (Source: McKesson News)
Source: McKesson News - November 19, 2020 Category: Information Technology Source Type: news

The US Oncology Network Enrolls 100,000th Patient in the Oncology Care Model, Enhancing Care While Saving Medicare over $100 Million
THE WOODLANDS, TEXAS, Nov. 11, 2020 —The US Oncology Network (The Network) reached a major milestone recently in its journey to provide high-quality, value-based care to local communities by enrolling its 100,000th patient in the Centers for Medicare& Medicaid Innovation ’s (CMMI) Oncology Care Model... (Source: McKesson News)
Source: McKesson News - November 11, 2020 Category: Information Technology Source Type: news

McKesson Joins United Nations Global Compact Initiative
IRVING, Texas, Nov. 10, 2020 – McKesson Corporation, a global healthcare leader, joins the United Nations (UN) Global Compact initiative, a voluntary leadership platform focused on the development, implementation and disclosure of responsible business practices. (Source: McKesson News)
Source: McKesson News - November 10, 2020 Category: Information Technology Source Type: news

McKesson Reports Fiscal 2021 Second-Quarter Results
Second-Quarter Highlights, Year-over-Year: (Source: McKesson News)
Source: McKesson News - November 3, 2020 Category: Information Technology Source Type: news

Walgreens Boots Alliance and McKesson Complete the Formation of German Wholesale Joint Venture
DEERFIELD, Ill.& IRVING, Texas —(BUSINESS WIRE)—Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) today announced the completion of their previously announced agreement to create a joint venture combining their respective pharmaceutical wholesale businesses in Germany, Alli... (Source: McKesson News)
Source: McKesson News - November 2, 2020 Category: Information Technology Source Type: news

McKesson Declares Quarterly Dividend
IRVING, Texas, October 29, 2020 —The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 42 cents per share of common stock. The dividend will be payable on January 4, 2021, to stockholders of record on December 1, 2020. (Source: McKesson News)
Source: McKesson News - October 29, 2020 Category: Information Technology Source Type: news

Providing Care in a Pandemic and Beyond: Three Considerations for Hospital Leaders
IRVING, Texas, Oct. 27 —McKesson, a global healthcare company, unveils three key considerations for hospital leadership following the historic challenges COVID-19 brought to America’s healthcare system. This includes a renewed focus on achieving tighter operational efficiencies; anticipating greater ... (Source: McKesson News)
Source: McKesson News - October 27, 2020 Category: Information Technology Source Type: news

The US Oncology Network continues to grow, enhancing community cancer care by welcoming two more practices
THE WOODLANDS, Texas, Oct. 22, 2020 — The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities by welcoming Alliance Cancer Specialists and Northwest Oncology.... (Source: McKesson News)
Source: McKesson News - October 22, 2020 Category: Information Technology Source Type: news